{
  "drug_name": "Andexanet_alfa",
  "url": "https://wikem.org/wiki/Andexanet_alfa",
  "scraped_at": "2026-01-10T02:57:30.381459",
  "sections": {
    "Adult_Dosing": {
      "text": "",
      "subsections": {
        "Determined_by_last_dose,_type_of_factor_Xa_inhibitor,_and_dose_of_inhibitor": {
          "text": "Last dose >8 hours ago\nLow dose\nLast dose <8 hours or unknown\nApixaban\n<5 mg: Low dose\n>5 mg/unknown: High dose\nRivaroxaban\n<10 mg: Low dose\n>10 mg/unknown: High dose",
          "tables": []
        },
        "Low_Dose": {
          "text": "400\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n4\nmg/minute for up to 120 minutes",
          "tables": []
        },
        "High_Dose": {
          "text": "800\nmg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by\n8\nmg/minute for up to 120 minutes",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "Apixaban",
          "url": "https://wikem.org/wiki/Apixaban"
        },
        {
          "text": "Rivaroxaban",
          "url": "https://wikem.org/wiki/Rivaroxaban"
        }
      ]
    },
    "Special_Populations": {
      "text": "",
      "subsections": {
        "Pregnancy_Rating": {
          "text": "not known",
          "tables": []
        },
        "Lactation_risk": {
          "text": "not known",
          "tables": []
        },
        "Renal_Dosing": {
          "text": "None",
          "tables": []
        },
        "Hepatic_Dosing": {
          "text": "None",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Contraindications": {
      "text": "Allergy to class/drug",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Arterial and venous thromboembolism\nDVT\n(6%)\nIschemic stroke\n(5%)\nMyocardial infarction\n(3%)\nPulmonary embolism\n(3%)\nAcute Respiratory failure (1%)\nCardiac arrest\nSudden death",
          "tables": []
        },
        "Common": {
          "text": "Infusion site reaction\nUTI (5%)\nPneumonia (5%)",
          "tables": []
        }
      },
      "tables": [],
      "links": [
        {
          "text": "DVT",
          "url": "https://wikem.org/wiki/DVT"
        },
        {
          "text": "Ischemic stroke",
          "url": "https://wikem.org/wiki/Ischemic_stroke"
        },
        {
          "text": "Myocardial infarction",
          "url": "https://wikem.org/wiki/Myocardial_infarction"
        },
        {
          "text": "Pulmonary embolism",
          "url": "https://wikem.org/wiki/Pulmonary_embolism"
        },
        {
          "text": "Cardiac arrest",
          "url": "https://wikem.org/wiki/Cardiac_arrest"
        }
      ]
    },
    "Pharmacology": {
      "text": "Half-life: 5 to 7 hours",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Comments": {
      "text": "FDA approved in May 2018, limited availability June 2018 with broader commercial launch in early 2019\nCost, $3,300 per 100 mg vial",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}